CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New way to deliver chemotherapy shows promise for stomach cancer patients
Disease control OngoingThis early-phase study is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study includes about…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:42 UTC
-
Two-Drug combo shows promise against tough cancers
Disease control OngoingThis early-phase trial tests a new combination of two drugs—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Sonidegib blocks certain enzymes that help cancer gr…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 01, 2026 15:38 UTC
-
New drug combo fails to shrink tumors in stomach cancer trial
Disease control OngoingThis study tested a combination of two drugs, berzosertib and irinotecan, in 17 patients with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combi…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC